$SUPN
SUPERNUS PHARMACEUTICALS, INC. Stock $supn

$supn Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000135657620000010 Filed on February 28, 2020

Income Statement

Concept	2019 Q4	2019 Q3	2019 Q2
Revenue	$100.4M	$102.1M	$104.7M
YoY Change	-13.36%	-0.83%	5.18%
Cost Of Revenue	$4.100M	$4.819M	$4.044M
YoY Change	-2.38%	14.55%	9.8%
Gross Profit	$96.30M	$97.32M	$100.7M
YoY Change	-13.79%	-1.49%	5.0%
Gross Profit Margin	95.87%	95.28%	96.14%
Selling, General & Admin	$35.70M	$39.34M	$39.78M
YoY Change	-15.2%	-3.79%	-0.8%
% of Gross Profit	37.07%	40.43%	39.52%
Research & Development	$19.80M	$16.94M	$16.97M
YoY Change	-33.56%	-17.04%	-15.31%
% of Gross Profit	20.56%	17.41%	16.86%
Depreciation & Amortization	$1.700M	$1.600M	$1.700M
YoY Change	0.0%	-15.79%	-5.56%
% of Gross Profit	1.77%	1.64%	1.69%
Operating Expenses	$55.50M	$56.29M	$56.75M
YoY Change	-22.81%	-8.2%	-5.63%
Operating Profit	$40.82M	$39.73M	$42.60M
YoY Change	2.41%	6.01%	19.26%
Interest Expense	-$3.300M	$5.662M	$5.389M
YoY Change	-3400.0%	5562.0%	-869.86%
% of Operating Profit	-8.09%	14.25%	12.65%
Other Income/Expense, Net	$3.400M	-$139.0K	$148.0K
YoY Change	-383.33%	-87.41%	-107.94%
Pretax Income	$40.90M	$39.59M	$42.75M
YoY Change	5.41%	8.85%	26.26%
Income Tax	$7.800M	$10.73M	$10.02M
% Of Pretax Income	19.07%	27.1%	23.44%
Net Earnings	$33.13M	$28.86M	$32.73M
YoY Change	27.95%	3.03%	6.47%
Net Earnings / Revenue	32.98%	28.26%	31.26%
Basic Earnings Per Share	$0.63	$0.55	$0.62
Diluted Earnings Per Share	$0.62	$0.54	$0.61
COMMON SHARES
Basic Shares Outstanding	52.46M shares	52.45M shares	52.39M shares
Diluted Shares Outstanding		53.81M shares	53.91M shares

Balance Sheet

Concept	2019 Q4	2019 Q3	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$347.1M	$296.7M	$258.6M
YoY Change	-2.5%	5.89%	48.28%
Cash & Equivalents	$181.4M	$116.9M	$87.34M
Short-Term Investments	$165.7M	$179.8M	$171.2M
Other Short-Term Assets	$11.60M	$18.20M	$21.80M
YoY Change	30.34%	95.7%	49.32%
Inventory	$26.63M	$25.50M	$26.02M
Prepaid Expenses
Receivables	$87.33M	$86.70M	$84.56M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$472.6M	$427.1M	$390.9M
YoY Change	-4.22%	9.34%	37.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$17.07M	$9.977M	$4.028M
YoY Change	316.8%	44.59%	-17.8%
Goodwill	$0.00
YoY Change
Intangibles	$24.84M	$26.10M	$28.79M
YoY Change	-20.81%
Long-Term Investments	$591.8M	$596.4M	$593.8M
YoY Change	41.31%	29.57%	17.98%
Other Assets	$21.89M	$574.0K	$581.0K
YoY Change	5661.58%	-98.21%	-97.79%
Total Long-Term Assets	$687.6M	$679.8M	$672.8M
YoY Change	41.98%	27.81%	18.38%
TOTAL ASSETS
Total Short-Term Assets	$472.6M	$427.1M	$390.9M
Total Long-Term Assets	$687.6M	$679.8M	$672.8M
Total Assets	$1.160B	$1.107B	$1.064B
YoY Change	18.66%	19.99%	24.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.14M	$3.090M	$4.081M
YoY Change	217.4%	-68.47%	40.72%
Accrued Expenses	$49.71M	$138.9M	$134.5M
YoY Change	36.07%	17.61%	35.45%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$160.6M	$149.7M	$144.0M
YoY Change	-0.47%	8.26%	38.57%
LONG-TERM LIABILITIES
Long-Term Debt	$345.2M	$341.2M	$337.2M
YoY Change	4.76%	4.76%	4.75%
Other Long-Term Liabilities	$28.66M	$11.21M	$10.96M
YoY Change	151.42%	-69.37%	-69.99%
Total Long-Term Liabilities	$28.66M	$11.21M	$10.96M
YoY Change	151.42%	-96.91%	-96.94%
TOTAL LIABILITIES
Total Short-Term Liabilities	$160.6M	$149.7M	$144.0M
Total Long-Term Liabilities	$28.66M	$11.21M	$10.96M
Total Liabilities	$564.9M	$549.7M	$540.8M
YoY Change	7.63%	9.8%	16.97%
SHAREHOLDERS EQUITY
Retained Earnings	$199.5M	$166.4M	$137.6M
YoY Change	130.71%
Common Stock	$53.00K	$52.00K	$52.00K
YoY Change	1.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$595.4M	$557.3M	$522.9M
YoY Change
Total Liabilities & Shareholders Equity	$1.160B	$1.107B	$1.064B
YoY Change	18.66%	19.99%	24.73%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2019 Q2
OPERATING ACTIVITIES
Net Income	$33.13M	$28.86M	$32.73M
YoY Change	27.95%	3.03%	6.47%
Depreciation, Depletion And Amortization	$1.700M	$1.600M	$1.700M
YoY Change	0.0%	-15.79%	-5.56%
Cash From Operating Activities	$43.80M	$37.60M	$28.70M
YoY Change	33.13%	-39.74%	334.85%
INVESTING ACTIVITIES
Capital Expenditures	-$2.000M	-$500.0K	$0.00
YoY Change	1900.0%	400.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$21.50M	-$7.900M	-$65.80M
YoY Change	-37.68%	-130.98%	-84.4%
Cash From Investing Activities	$19.50M	-$8.400M	-$65.80M
YoY Change	-43.15%	-133.2%	-84.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.200M	300.0K	1.600M
YoY Change	0.0%	-62.5%	-76.12%
NET CHANGE
Cash From Operating Activities	43.80M	37.60M	28.70M
Cash From Investing Activities	19.50M	-8.400M	-65.80M
Cash From Financing Activities	1.200M	300.0K	1.600M
Net Change In Cash	64.50M	29.50M	-35.50M
YoY Change	-5.7%	-66.67%	-91.32%
FREE CASH FLOW
Cash From Operating Activities	$43.80M	$37.60M	$28.70M
Capital Expenditures	-$2.000M	-$500.0K	$0.00
Free Cash Flow	$45.80M	$38.10M	$28.70M
YoY Change	38.79%	-39.04%	315.94%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001356576
CY2018Q4	supn	Prelaunch Inventory Net PrelaunchInventoryNet	0	USD
CY2017	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	USD
CY2018	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019	dei	Entity Small Business EntitySmallBusiness	false
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52316583	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52533348	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52316583	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52533348	shares
CY2018Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	USD
CY2018Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2300000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	5000000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	5000000	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.6060
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.6056
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.6328
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0218
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0285
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0255
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Document Annual Report DocumentAnnualReport	true
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Entity File Number EntityFileNumber	001-35518
CY2019	dei	Document Transition Report DocumentTransitionReport	false
CY2019	dei	Entity Registrant Name EntityRegistrantName	SUPERNUS PHARMACEUTICALS, INC.
CY2019	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2019	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-2590184
CY2019	dei	Entity Address Address Line1 EntityAddressAddressLine1	9715 Key West Avenue
CY2019	dei	Entity Address City Or Town EntityAddressCityOrTown	Rockville
CY2019	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2019	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20850
CY2019	dei	City Area Code CityAreaCode	(301)
CY2019	dei	Local Phone Number LocalPhoneNumber	838-2500
CY2019	dei	Security12b Title Security12bTitle	Common Stock, $0.001 Par Value
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	52533973	shares
CY2019	dei	Trading Symbol TradingSymbol	SUPN
CY2019	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2019Q4	supn	Non Recourse Debt Sale Of Future Royalties Current NonRecourseDebtSaleOfFutureRoyaltiesCurrent	3244000	USD
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019Q2	dei	Entity Public Float EntityPublicFloat	1677874611	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	181381000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	192248000	USD
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	165692000	USD
CY2018Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	163770000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	87332000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	102922000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	26628000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	25659000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11611000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8888000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	472644000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	493487000	USD
CY2019Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	591773000	USD
CY2018Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	418798000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17068000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4095000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	24840000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	31368000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21279000	USD
CY2019Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	32063000	USD
CY2018Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	29683000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	615000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	380000	USD
CY2019Q4	us-gaap	Assets Assets	1160282000	USD
CY2018Q4	us-gaap	Assets Assets	977811000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10141000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3195000	USD
CY2019Q4	supn	Accrued Product Returns And Rebates AccruedProductReturnsAndRebates	107629000	USD
CY2018Q4	supn	Accrued Product Returns And Rebates AccruedProductReturnsAndRebates	107063000	USD
CY2019Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	37130000	USD
CY2018Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	36535000	USD
CY2019Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2443000	USD
CY2019Q4	supn	Non Recourse Debt Sale Of Future Royalties Noncurrent NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent	19248000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	564854000	USD
CY2018Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	12377000	USD
CY2018Q4	supn	Non Recourse Debt Sale Of Future Royalties Noncurrent NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent	22575000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30440000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	99541000	USD
CY2018Q4	supn	Non Recourse Debt Sale Of Future Royalties Current NonRecourseDebtSaleOfFutureRoyaltiesCurrent	2183000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	160587000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	161353000	USD
CY2019Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	345170000	USD
CY2018Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	329462000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9409000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	11398000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	524788000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	53000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	52000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	388410000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	369637000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	7417000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3158000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	199548000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	86492000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	595428000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	453023000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1160282000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	977811000	USD
CY2019	us-gaap	Revenues Revenues	392755000	USD
CY2018	us-gaap	Revenues Revenues	408897000	USD
CY2017	us-gaap	Revenues Revenues	302238000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	16660000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	15356000	USD
CY2017	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	15215000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	69099000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	89209000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	49577000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	158425000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	159888000	USD
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	137905000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	244184000	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	264453000	USD
CY2017	us-gaap	Costs And Expenses CostsAndExpenses	202697000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	148571000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	140176000	USD
CY2019	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	22707000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	144444000	USD
CY2017	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2645000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1084000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4268000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1077000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	147487000	USD
CY2019	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	21623000	USD
CY2018	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	13843000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	56671000	USD
CY2018	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	18111000	USD
CY2017	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1568000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	100618000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	34431000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29183000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	43334000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	113056000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	110993000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	57284000	USD
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.16
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.13
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.13
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.10
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.05
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.08
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52412181	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51989824	shares
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50756603	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53816754	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54098872	shares
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53301150	shares
CY2019	us-gaap	Net Income Loss NetIncomeLoss	113056000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	110993000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	57284000	USD
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	10575000	USD
CY2018	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-2411000	USD
CY2017	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-613000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	10575000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2411000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-613000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	123631000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	108582000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	191755000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	8433000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11291000	USD
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2209000	USD
CY2017Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest Adjusted Balance1 StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	192147000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8433000	USD
CY2018	supn	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	9373000	USD
CY2017	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1888000	USD
CY2017	supn	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	3793000	USD
CY2018	supn	Stock Issued During Period Value Conversion Of Convertible Notes StockIssuedDuringPeriodValueConversionOfConvertibleNotes	56215000	USD
CY2018	supn	Purchases Of Convertible Note Hedges Net Of Tax PurchasesOfConvertibleNoteHedgesNetOfTax	-70137000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	65688000	USD
CY2017	supn	Stock Issued During Period Value Conversion Of Convertible Notes StockIssuedDuringPeriodValueConversionOfConvertibleNotes	4548000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	57284000	USD
CY2017	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-613000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	267480000	USD
CY2018Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest Adjusted Balance1 StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	269802000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	110993000	USD
CY2018	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-2411000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	453023000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14846000	USD
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2448000	USD
CY2019	supn	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	1480000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	113056000	USD
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	10575000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	595428000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	113056000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	110993000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	57284000	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-295000	USD
CY2019	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2018	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2017	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	76000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6659000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7063000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8132000	USD
CY2019	supn	Noncash Operating Lease Cost NoncashOperatingLeaseCost	3566000	USD
CY2018	supn	Noncash Operating Lease Cost NoncashOperatingLeaseCost	0	USD
CY2017	supn	Noncash Operating Lease Cost NoncashOperatingLeaseCost	0	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	15708000	USD
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	11848000	USD
CY2017	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	50000	USD
CY2019	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	4335000	USD
CY2018	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	1665000	USD
CY2017	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	563000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	11291000	USD
CY2019	supn	Interest Expense Non Recourse Royalty Liability InterestExpenseNonRecourseRoyaltyLiability	5775000	USD
CY2018	supn	Interest Expense Non Recourse Royalty Liability InterestExpenseNonRecourseRoyaltyLiability	4271000	USD
CY2017	supn	Interest Expense Non Recourse Royalty Liability InterestExpenseNonRecourseRoyaltyLiability	1434000	USD
CY2019	supn	Revenue From Royalty Agreement RevenueFromRoyaltyAgreement	6927000	USD
CY2018	supn	Revenue From Royalty Agreement RevenueFromRoyaltyAgreement	5914000	USD
CY2017	supn	Revenue From Royalty Agreement RevenueFromRoyaltyAgreement	5283000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	14846000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5832000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4167000	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	21224000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-15751000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	35856000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	24059000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	969000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9355000	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-497000	USD
CY2019	supn	Increase Decrease In Prepaid Deferred Expense And Other Current Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets	2723000	USD
CY2018	supn	Increase Decrease In Prepaid Deferred Expense And Other Current Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets	2367000	USD
CY2017	supn	Increase Decrease In Prepaid Deferred Expense And Other Current Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets	3566000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	141000	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2017	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6962000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3578000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-620000	USD
CY2019	supn	Increase Decrease In Accrued Product Returns And Rebates IncreaseDecreaseInAccruedProductReturnsAndRebates	566000	USD
CY2018	supn	Increase Decrease In Accrued Product Returns And Rebates IncreaseDecreaseInAccruedProductReturnsAndRebates	38720000	USD
CY2017	supn	Increase Decrease In Accrued Product Returns And Rebates IncreaseDecreaseInAccruedProductReturnsAndRebates	26400000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3811000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	10432000	USD
CY2017	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2888000	USD
CY2019	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-9934000	USD
CY2018	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-3561000	USD
CY2017	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	15931000	USD
CY2019	supn	Increase Decrease In Deferred Licensing Revenue IncreaseDecreaseInDeferredLicensingRevenue	0	USD
CY2018	supn	Increase Decrease In Deferred Licensing Revenue IncreaseDecreaseInDeferredLicensingRevenue	0	USD
CY2017	supn	Increase Decrease In Deferred Licensing Revenue IncreaseDecreaseInDeferredLicensingRevenue	-274000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-5088000	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	831000	USD
CY2017	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	6513000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	143129000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	128986000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	114640000	USD
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	409707000	USD
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	491654000	USD
CY2017	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	101889000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	253170000	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	79827000	USD
CY2017	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	28657000	USD
CY2019	supn	Debt Conversion Converted Instrument And Interest Make Whole Amount DebtConversionConvertedInstrumentAndInterestMakeWholeAmount	0	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2736000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	844000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2029000	USD
CY2019	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	1349000	USD
CY2018	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	809000	USD
CY2017	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	11154000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-157924000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-413480000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-86415000	USD
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2018	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	402500000	USD
CY2017	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2019	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0	USD
CY2018	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	10435000	USD
CY2017	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	65688000	USD
CY2017	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
CY2019	supn	Purchases Of Convertible Note Hedge PurchasesOfConvertibleNoteHedge	0	USD
CY2018	supn	Purchases Of Convertible Note Hedge PurchasesOfConvertibleNoteHedge	92897000	USD
CY2017	supn	Purchases Of Convertible Note Hedge PurchasesOfConvertibleNoteHedge	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3928000	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11582000	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5681000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3928000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	376438000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5681000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10867000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	91944000	USD
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	33906000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	192248000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100304000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66398000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	181381000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	192248000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100304000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	2516000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	1342000	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	134000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	51540000	USD
CY2017	supn	Unsettled Purchase Of Marketable Securities Included In Accrued Expenses UnsettledPurchaseOfMarketableSecuritiesIncludedInAccruedExpenses	1004000	USD
CY2019	supn	Property And Equipment Additions From Utilization Of Tenant Improvement Allowance PropertyAndEquipmentAdditionsFromUtilizationOfTenantImprovementAllowance	10151000	USD
CY2018	supn	Debt Conversion Converted Instrument And Interest Make Whole Amount DebtConversionConvertedInstrumentAndInterestMakeWholeAmount	0	USD
CY2018	supn	Property And Equipment Additions From Utilization Of Tenant Improvement Allowance PropertyAndEquipmentAdditionsFromUtilizationOfTenantImprovementAllowance	0	USD
CY2017	supn	Property And Equipment Additions From Utilization Of Tenant Improvement Allowance PropertyAndEquipmentAdditionsFromUtilizationOfTenantImprovementAllowance	0	USD
CY2017	supn	Debt Conversion Converted Instrument And Interest Make Whole Amount DebtConversionConvertedInstrumentAndInterestMakeWholeAmount	4548000	USD
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	34772000	USD
CY2017	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1588000	USD
CY2017	supn	Non Cash Capitalized Cost Of Intangible Assets NonCashCapitalizedCostOfIntangibleAssets	521000	USD
CY2019	supn	Unsettled Purchase Of Marketable Securities Included In Accrued Expenses UnsettledPurchaseOfMarketableSecuritiesIncludedInAccruedExpenses	0	USD
CY2018	supn	Unsettled Purchase Of Marketable Securities Included In Accrued Expenses UnsettledPurchaseOfMarketableSecuritiesIncludedInAccruedExpenses	0	USD
CY2019	supn	Non Cash Capitalized Cost Of Intangible Assets NonCashCapitalizedCostOfIntangibleAssets	1832000	USD
CY2018	supn	Non Cash Capitalized Cost Of Intangible Assets NonCashCapitalizedCostOfIntangibleAssets	250000	USD
CY2019	us-gaap	Nature Of Operations NatureOfOperations	Organization and Nature of Operations<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supernus Pharmaceuticals, Inc. (the Company) was incorporated in Delaware and commenced operations in 2005. The Company is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> products: Oxtellar XR for the treatment of epilepsy and Trokendi XR for the prophylaxis of migraine headache and the treatment of epilepsy. The Company is also developing multiple proprietary CNS product candidates to address significant unmet medical needs and market opportunities.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company launched Oxtellar XR and Trokendi XR for the treatment of epilepsy in 2013, followed by the launch of Trokendi XR for the prophylaxis of migraine headache in adolescents and adults in April 2017. The Company launched Oxtellar XR with an expanded indication to include monotherapy for partial seizures in January 2019.</span></div>
CY2019	supn	Number Of Proprietary Commercial Products NumberOfProprietaryCommercialProducts	2	product
CY2019	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<div style="line-height:120%;padding-top:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company bases its estimates on: historical experience; various forecasts; information received from its service providers and from other sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company evaluates the methodologies employed in making its estimates on an ongoing basis.</span></div>
CY2018Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	67206000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2019	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	USD
CY2019	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="line-height:120%;padding-top:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentration of Credit Risk</span></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. The counterparties are various corporations, governmental institutions, and financial institutions of high credit standing.</span></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Substantially all of the Company's cash and cash equivalents and marketable securities are maintained in U.S. government agency debt and debt of well-known, investment grade corporations. Deposits held with banks may exceed the amount of governmental insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, these bear minimal default risk.</span></div>
CY2019Q4	supn	Prelaunch Inventory Net PrelaunchInventoryNet	0	USD
CY2019Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	USD
CY2019	supn	Sales Return Period Prior To Expiration SalesReturnPeriodPriorToExpiration	P6M
CY2019	supn	Sales Return Period SalesReturnPeriod	P12M
CY2019	supn	Number Of Commercial Products NumberOfCommercialProducts	2	product
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2018Q1	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	20109000	USD
CY2019	supn	Threshold Limit For Medical Claim ThresholdLimitForMedicalClaim	150000	USD
CY2019Q4	supn	Self Insurance Liability SelfInsuranceLiability	600000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	37130000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	36535000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	747598000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	586726000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	10031000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	55000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	164000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4213000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	757465000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	582568000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	165692000	USD
CY2019Q4	supn	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	188378000	USD
CY2019Q4	supn	Available For Sale Securities Debt Maturities Two Years Through Three Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesTwoYearsThroughThreeYearsFairValue	201491000	USD
CY2019Q4	supn	Available For Sale Securities Debt Maturities Three Years Through Four Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesThreeYearsThroughFourYearsFairValue	201904000	USD
CY2019Q4	supn	Available For Sale Securities Debt Maturities Thereafter Fair Value AvailableForSaleSecuritiesDebtMaturitiesThereafterFairValue	0	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	757465000	USD
CY2019Q4	us-gaap	Inventory Work In Process And Raw Materials Net Of Reserves InventoryWorkInProcessAndRawMaterialsNetOfReserves	4582000	USD
CY2018Q4	us-gaap	Inventory Work In Process And Raw Materials Net Of Reserves InventoryWorkInProcessAndRawMaterialsNetOfReserves	5742000	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	11428000	USD
CY2018Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	7275000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	10618000	USD
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	12642000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	26628000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	25659000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	29767000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15314000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12699000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11219000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17068000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4095000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1500000	USD
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1900000	USD
CY2017	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1200000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	18535000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	13356000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	24840000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	31368000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5200000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5200000	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6900000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	5000000.0	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2300000	USD
CY2019Q4	supn	Accrued Clinical Trial And Clinical Supply Costs Current AccruedClinicalTrialAndClinicalSupplyCostsCurrent	13285000	USD
CY2018Q4	supn	Accrued Clinical Trial And Clinical Supply Costs Current AccruedClinicalTrialAndClinicalSupplyCostsCurrent	14034000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11223000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	13546000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3936000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3706000	USD
CY2019Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2825000	USD
CY2018Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5861000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5249000	USD
CY2019Q4	supn	Accrued Rebates AccruedRebates	88811000	USD
CY2018Q4	supn	Accrued Rebates AccruedRebates	85003000	USD
CY2019Q4	supn	Accrued Product Returns AccruedProductReturns	18818000	USD
CY2018Q4	supn	Accrued Product Returns AccruedProductReturns	22060000	USD
CY2019Q4	supn	Accrued Product Returns And Rebates AccruedProductReturnsAndRebates	107629000	USD
CY2018Q4	supn	Accrued Product Returns And Rebates AccruedProductReturnsAndRebates	107063000	USD
CY2018Q1	supn	Debt Instrument Covenant Percentage Of Last Reported Sales Price Threshold Per1000 Principal Amount DebtInstrumentCovenantPercentageOfLastReportedSalesPriceThresholdPer1000PrincipalAmount	0.98
CY2018Q1	supn	Purchases Of Convertible Note Hedge PurchasesOfConvertibleNoteHedge	92900000	USD
CY2018Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	80.9063
CY2018Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	65700000	USD
CY2018Q1	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	10400000	USD
CY2019	us-gaap	Interest Income Other InterestIncomeOther	21623000	USD
CY2018	us-gaap	Interest Income Other InterestIncomeOther	13843000	USD
CY2017	us-gaap	Interest Income Other InterestIncomeOther	2864000	USD
CY2019	us-gaap	Interest Expense InterestExpense	18207000	USD
CY2018	us-gaap	Interest Expense InterestExpense	13840000	USD
CY2017	us-gaap	Interest Expense InterestExpense	134000	USD
CY2019	us-gaap	Interest Expense Other InterestExpenseOther	4500000	USD
CY2018	us-gaap	Interest Expense Other InterestExpenseOther	4271000	USD
CY2017	us-gaap	Interest Expense Other InterestExpenseOther	1434000	USD
CY2019	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2018	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2017	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	76000	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-295000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1084000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4268000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1077000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	15700000	USD
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	11800000	USD
CY2019Q4	supn	Number Of Votes Per Common Share Held NumberOfVotesPerCommonShareHeld	1	vote
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14846000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11291000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8433000	USD
CY2019	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
CY2018	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
CY2017	us-gaap	Dilutive Securities DilutiveSecurities	32000	USD
CY2019	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	113056000	USD
CY2018	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	110993000	USD
CY2017	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	57316000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	108520000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	36317000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	57220000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2423000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	27716000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	27716000	USD
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	25594000	USD
CY2018Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	80.9063
CY2018Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	80.9063
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	113056000	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	110993000	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	57284000	USD
CY2019	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	USD
CY2018	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	USD
CY2017	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	134000	USD
CY2019	supn	Increase Decrease In Fair Value Derivative Liabilities IncreaseDecreaseInFairValueDerivativeLiabilities	0	USD
CY2018	supn	Increase Decrease In Fair Value Derivative Liabilities IncreaseDecreaseInFairValueDerivativeLiabilities	0	USD
CY2017	supn	Increase Decrease In Fair Value Derivative Liabilities IncreaseDecreaseInFairValueDerivativeLiabilities	-76000	USD
CY2019	supn	Gains Losses On Extinguishment Of Outstanding Debt GainsLossesOnExtinguishmentOfOutstandingDebt	0	USD
CY2018	supn	Gains Losses On Extinguishment Of Outstanding Debt GainsLossesOnExtinguishmentOfOutstandingDebt	0	USD
CY2017	supn	Gains Losses On Extinguishment Of Outstanding Debt GainsLossesOnExtinguishmentOfOutstandingDebt	295000	USD
CY2019	supn	Gains Losses On Extinguishment Of Outstanding Debt As If Converted GainsLossesOnExtinguishmentOfOutstandingDebtAsIfConverted	0	USD
CY2018	supn	Gains Losses On Extinguishment Of Outstanding Debt As If Converted GainsLossesOnExtinguishmentOfOutstandingDebtAsIfConverted	0	USD
CY2017	supn	Gains Losses On Extinguishment Of Outstanding Debt As If Converted GainsLossesOnExtinguishmentOfOutstandingDebtAsIfConverted	-321000	USD
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52412181	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51989824	shares
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50756603	shares
CY2019	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2018	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2017	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	285257	shares
CY2019	supn	Incremental Common Shares Attributable To Settlement Of Interest Make Whole Derivatives IncrementalCommonSharesAttributableToSettlementOfInterestMakeWholeDerivatives	0	shares
CY2018	supn	Incremental Common Shares Attributable To Settlement Of Interest Make Whole Derivatives IncrementalCommonSharesAttributableToSettlementOfInterestMakeWholeDerivatives	0	shares
CY2017	supn	Incremental Common Shares Attributable To Settlement Of Interest Make Whole Derivatives IncrementalCommonSharesAttributableToSettlementOfInterestMakeWholeDerivatives	7012	shares
CY2019	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1404573	shares
CY2018	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2109048	shares
CY2017	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2252278	shares
CY2019	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1404573	shares
CY2018	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	2109048	shares
CY2017	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	2544547	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53816754	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54098872	shares
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53301150	shares
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.16
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.13
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.13
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.10
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.05
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.08
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	29333000	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	26772000	USD
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	18288000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	10930000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5621000	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3822000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-4551000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2450000	USD
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	21493000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1281000	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-760000	USD
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-269000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	34431000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29183000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	43334000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	30972000	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	29437000	USD
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	35217000	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	7543000	USD
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	3674000	USD
CY2017	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	2714000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1332000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-2196000	USD
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-2311000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	2071000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	3199000	USD
CY2017	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	2196000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-2992000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	716000	USD
CY2017	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-1137000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	9694000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-353000	USD
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	751000	USD
CY2017	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1353000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	34431000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29183000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	43334000	USD
CY2019Q4	supn	Deferred Tax Assets Convertible Bond Hedge DeferredTaxAssetsConvertibleBondHedge	17197000	USD
CY2018Q4	supn	Deferred Tax Assets Convertible Bond Hedge DeferredTaxAssetsConvertibleBondHedge	21412000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	15123000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	13205000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	10349000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	8218000	USD
CY2019Q4	supn	Deferred Tax Assets Royalty Revenue DeferredTaxAssetsRoyaltyRevenue	5320000	USD
CY2018Q4	supn	Deferred Tax Assets Royalty Revenue DeferredTaxAssetsRoyaltyRevenue	5571000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3817000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3817000	USD
CY2019Q4	supn	Deferred Tax Asset Amortization DeferredTaxAssetAmortization	4617000	USD
CY2018Q4	supn	Deferred Tax Asset Amortization DeferredTaxAssetAmortization	3289000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2245000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2900000	USD
CY2019Q4	supn	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	8187000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	1385000	USD
CY2019	supn	Net Operating Loss Carryforward Utilized NetOperatingLossCarryforwardUtilized	10200000	USD
CY2019Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	4200000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	69354000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	61148000	USD
CY2019Q4	supn	Deferred Tax Liabilities Debt Discount On Convertible Notes DeferredTaxLiabilitiesDebtDiscountOnConvertibleNotes	14109000	USD
CY2018Q4	supn	Deferred Tax Liabilities Debt Discount On Convertible Notes DeferredTaxLiabilitiesDebtDiscountOnConvertibleNotes	17568000	USD
CY2019Q4	supn	Deferred Tax Liabilities Infringement Legal Cost DeferredTaxLiabilitiesInfringementLegalCost	10613000	USD
CY2018Q4	supn	Deferred Tax Liabilities Infringement Legal Cost DeferredTaxLiabilitiesInfringementLegalCost	10697000	USD
CY2019Q4	supn	Deferred Tax Liability Operating Lease Assets DeferredTaxLiabilityOperatingLeaseAssets	5237000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	499000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax	926000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax	978000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	199000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1268000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	69365000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	61157000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	9000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	2778000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	236000	USD
CY2019Q4	supn	Deferred Tax Liabilities481a Adjustment DeferredTaxLiabilities481aAdjustment	2126000	USD
CY2018Q4	supn	Deferred Tax Liabilities481a Adjustment DeferredTaxLiabilities481aAdjustment	2964000	USD
CY2019Q4	supn	Deferred Tax Liabilities Unrealized Gain On Marketable Securities DeferredTaxLiabilitiesUnrealizedGainOnMarketableSecurities	2428000	USD
CY2018Q4	supn	Deferred Tax Liabilities Unrealized Gain On Marketable Securities DeferredTaxLiabilitiesUnrealizedGainOnMarketableSecurities	0	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	37291000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	31465000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	32063000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	29683000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8848000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8859000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9299000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	208000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1108000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1178000	USD
CY2019	supn	Operating Lease Fixed Lease Cost OperatingLeaseFixedLeaseCost	4990000	USD
CY2019	supn	Operating Lease Variable Lease Cost OperatingLeaseVariableLeaseCost	1887000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	947000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	49000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	484000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	3029000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	635000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2019	supn	Unrecognized Tax Benefits Change In Tax Rates UnrecognizedTaxBenefitsChangeInTaxRates	0	USD
CY2018	supn	Unrecognized Tax Benefits Change In Tax Rates UnrecognizedTaxBenefitsChangeInTaxRates	0	USD
CY2017	supn	Unrecognized Tax Benefits Change In Tax Rates UnrecognizedTaxBenefitsChangeInTaxRates	-2565000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5978000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8848000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8859000	USD
CY2019	supn	Income Tax Expense On Uncertain Tax Position Alternate Minimum Tax IncomeTaxExpenseOnUncertainTaxPositionAlternateMinimumTax	3000000.0	USD
CY2018	supn	Income Tax Expense On Uncertain Tax Position Alternate Minimum Tax IncomeTaxExpenseOnUncertainTaxPositionAlternateMinimumTax	600000	USD
CY2019	supn	Income Tax Expense On Uncertain Tax Position IncomeTaxExpenseOnUncertainTaxPosition	200000	USD
CY2018	supn	Income Tax Expense On Uncertain Tax Position IncomeTaxExpenseOnUncertainTaxPosition	300000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21279000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2825000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30440000	USD
CY2019Q4	supn	Lessee Operating Lease Liabilities LesseeOperatingLeaseLiabilities	33265000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	6877000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	33265000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	5337000	USD
CY2018	supn	Operating Leases Rent Payments OperatingLeasesRentPayments	5196000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	35594000	USD
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y5M23D
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0439
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4212000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4130000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3597000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2537000	USD
CY2019Q4	supn	Lessee Operating Lease Liability Payments Due Thereafter LesseeOperatingLeaseLiabilityPaymentsDueThereafter	29372000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	43848000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	10583000	USD
CY2018	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	3600000	USD
CY2017	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2700000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	3400000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2287000	USD
CY2018Q4	supn	Operating Leases Future Minimum Payments Thereafter Due OperatingLeasesFutureMinimumPaymentsThereafterDue	1840000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	7527000	USD
CY2019Q4	supn	Allowance For Expected Sales Deductions AllowanceForExpectedSalesDeductions	11000000.0	USD
CY2018Q4	supn	Allowance For Expected Sales Deductions AllowanceForExpectedSalesDeductions	11500000	USD
CY2019	us-gaap	Revenues Revenues	392755000	USD
CY2018	us-gaap	Revenues Revenues	408897000	USD
CY2017	us-gaap	Revenues Revenues	302238000	USD
CY2019	supn	Revenue From Royalty Agreement RevenueFromRoyaltyAgreement	6900000	USD
CY2018	supn	Revenue From Royalty Agreement RevenueFromRoyaltyAgreement	5900000	USD
CY2017	supn	Revenue From Royalty Agreement RevenueFromRoyaltyAgreement	5300000	USD
CY2014Q3	supn	Non Recourse Debt Sale Of Future Royalties Noncurrent NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent	30000000.0	USD
CY2019	supn	Defined Contribution Plan Eligibility Minimum Age DefinedContributionPlanEligibilityMinimumAge	P18Y
CY2019	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.90
CY2019	supn	Defined Contribution Plan Employer Match Level One DefinedContributionPlanEmployerMatchLevelOne	1
CY2019	supn	Defined Contribution Plan Employer Match Employee Contribution Level One DefinedContributionPlanEmployerMatchEmployeeContributionLevelOne	0.03
CY2019	supn	Defined Contribution Plan Employer Match Level Two DefinedContributionPlanEmployerMatchLevelTwo	0.50
CY2019	supn	Employer Match Employee Contribution Level Two EmployerMatchEmployeeContributionLevelTwo	0.02
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	30737000	USD
CY2019Q2	us-gaap	Revenues Revenues	104695000	USD
CY2019Q3	us-gaap	Revenues Revenues	102140000	USD
CY2019Q4	us-gaap	Revenues Revenues	100446000	USD
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	60046000	USD
CY2019Q2	us-gaap	Costs And Expenses CostsAndExpenses	62097000	USD
CY2019Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.61
CY2019	supn	Defined Contribution Plan Maximum Discretionary Employer Contribution Percentage DefinedContributionPlanMaximumDiscretionaryEmployerContributionPercentage	0.60
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2300000	USD
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2100000	USD
CY2017	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1800000	USD
CY2019Q1	us-gaap	Revenues Revenues	85474000	USD
CY2019Q3	us-gaap	Costs And Expenses CostsAndExpenses	62411000	USD
CY2019Q4	us-gaap	Costs And Expenses CostsAndExpenses	59630000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	25428000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	42598000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	39729000	USD
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	40816000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	18340000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	32727000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	28860000	USD
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	33129000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.35
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.62
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.55
CY2019Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.63
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.34
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.54
CY2019Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.62
CY2018Q1	us-gaap	Revenues Revenues	90429000	USD
CY2018Q2	us-gaap	Revenues Revenues	99538000	USD
CY2018Q3	us-gaap	Revenues Revenues	102996000	USD
CY2018Q4	us-gaap	Revenues Revenues	115934000	USD
CY2018Q1	us-gaap	Costs And Expenses CostsAndExpenses	59035000	USD
CY2018Q2	us-gaap	Costs And Expenses CostsAndExpenses	63818000	USD
CY2018Q3	us-gaap	Costs And Expenses CostsAndExpenses	65521000	USD
CY2018Q4	us-gaap	Costs And Expenses CostsAndExpenses	76079000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	31394000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	35720000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	37475000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	28011000	USD
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	25893000	USD
CY2018Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	39855000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	26352000	USD
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.51
CY2018Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.59
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.54
CY2018Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.50
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.49
CY2018Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.57
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.52
CY2018Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.48

Files In Submission

Name	View Source	Status
0001356576-20-000010-index-headers.html	Edgar Link	pending
0001356576-20-000010-index.html	Edgar Link	pending
0001356576-20-000010.txt	Edgar Link	pending
0001356576-20-000010-xbrl.zip	Edgar Link	pending
a201910kitem5totalperformace.jpg	Edgar Link	pending
currentporfolioa04.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
prescriptions.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
supn-20191231.xsd	Edgar Link	pending
supn-20191231x10k.htm	Edgar Link	pending
supn-20191231x10k_htm.xml	Edgar Link	completed
supn-20191231xex21.htm	Edgar Link	pending
supn-20191231xex231.htm	Edgar Link	pending
supn-20191231xex311.htm	Edgar Link	pending
supn-20191231xex312.htm	Edgar Link	pending
supn-20191231xex321.htm	Edgar Link	pending
supn-20191231xex322.htm	Edgar Link	pending
supn-20191231_cal.xml	Edgar Link	unprocessable
supn-20191231_def.xml	Edgar Link	unprocessable
supn-20191231_lab.xml	Edgar Link	unprocessable
supn-20191231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SUPN
SUPERNUS PHARMACEUTICALS, INC. Stock $supn

2019 Q4 Form 10-K Financial Statement

#000135657620000010 Filed on February 28, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SUPN SUPERNUS PHARMACEUTICALS, INC. Stock $supn

2019 Q4 Form 10-K Financial Statement

#000135657620000010 Filed on February 28, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SUPN
SUPERNUS PHARMACEUTICALS, INC. Stock $supn